Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

AstraZeneca Symbicort U.S. Filing Awaits Results of Formoterol Trials

Executive Summary

A U.S. NDA filing for AstraZeneca's combination asthma therapy Symbicort awaits completion of Phase III trials of the beta agonist (formoterol) component.

You may also be interested in...



Novartis Foradil Higher-Dose Phase IV Studies Slated For Completion By 2003

Novartis will study higher doses of Foradil (formoterol) as a postmarketing commitment associated with FDA's Feb. 16 approval of the asthma therapy.

Novartis Foradil Higher-Dose Phase IV Studies Slated For Completion By 2003

Novartis will study higher doses of Foradil (formoterol) as a postmarketing commitment associated with FDA's Feb. 16 approval of the asthma therapy.

AstraZeneca Anticoagulant NDA Delayed; Crestor v. Lipitor Data In March

AstraZeneca plans to submit an NDA for the oral direct thrombin inhibitor H376/95 in the second half of 2002.

Related Content

UsernamePublicRestriction

Register

LL1129949

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel